A pharmacokinetic and safety study of single dose intravenous combretastatin A4 phosphate in Chinese patients with refractory solid tumours

    loading  Checking for direct PDF access through Ovid



This trial was conducted to evaluate the safety and pharmacokinetics of combretastatin A4 phosphate (CA4P) given intravenously as a single dose to Chinese patients with refractory solid tumours.


Twenty-five patients were treated with single doses of CA4P according to a dose escalation scheme: 5, 10, 20, 33, 50, 65 and 85 mg m−2 infused intravenously over 30 min.


CA4P was generally well tolerated at ≤65 mg m−2. Transient, moderate increases in the heart rate-corrected QT interval occurred at all doses. CA4P produced a transient dose-dependent increase in neural and gastrointestinal toxicities. Acute renal failure occurred in one dehydrated patient who had also taken paracetamol. There were seven episodes of dose-limiting toxicity at doses ≥65 mg m−2, including two episodes of reversible ataxia at 85 mg m−2. For CA4P, at 50 mg m−2, mean (SD) peak plasma concentration (Cmax) was 0.99 (0.33) μm, area under the curve from time zero to time of last quantifiable concentration (AUC(0,t)) was 1.42 (0.30) μm h and terminal elimination half-life (t1/2) was 1.81 (0.61) h. At 65 mg m−2, Cmax was 1.73 (0.62) μm, AUC(0,t) was 3.19 (1.47) μm h and t1/2 was 1.90 (0.61) h. One patient with nasopharyngeal carcinoma had an obvious clinical response with central necrosis in the metastatic lung mass.


Doses ≤65 mg m−2 given as 30 min infusions define the maximum tolerated dose in East Asian patients, and doses in the range of 50–65 mg m−2 have been selected for further studies.

Related Topics

    loading  Loading Related Articles